Search Within

Sarcoma Service

Formats
  1. Journal Article (455)
  2. Meeting Abstract (431)
  3. Review (29)
  4. Editorial (9)
  5. Guidelines (8)
  6. Book Section (6)
  7. Miscellaneous (6)
  8. Research Letter (6)
  9. Correspondence (2)
  10. Book Whole (1)
Groups
  1. Department of Medicine (953)
  2. Solid Tumor Oncology Division (953)
  3. GSK Faculty (343)
  4. Tow Center for Developmental Oncology (TCDO) (310)
  5. Hematologic Malignancies, Division of (295)
  6. Department of Pathology and Laboratory Medicine (241)

More Groups

People
  1. William Tap (382)
  2. Sandra D'Angelo (256)
  3. Mrinal Gounder (232)
  4. Ping Chi (177)
  5. Mark Dickson (173)
  6. Cristina Antonescu (138)

More People

Years
  1. 2025 (44)
  2. 2024 (87)
  3. 2023 (79)
  4. 2022 (116)
  5. 2021 (76)
  6. 2020 (90)

More Years

Publications
  1. Journal of Clinical Oncology (274)
  2. Annals of Oncology (70)
  3. Clinical Cancer Research (61)
  4. Cancer Research (31)
  5. Journal for ImmunoTherapy of Cancer (28)
  6. Cancer (19)

More Publications

Publishers
  1. American Society of Clinical Oncology (288)
  2. American Association for Cancer Research (108)
  3. Oxford University Press (92)
  4. Elsevier Inc. (57)
  5. Nature Publishing Group (42)
  6. Springer (40)

More Publishers

Results (953)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors
    Meeting Abstract

    LoRusso, P.; Gounder, M. M.; Patel, M. R.; Yamamoto, N.; Bauer, T. M.; Laurie, S.; Grempler, R.; Davenport, T.; Geng, J.; Rohrbacher, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma
    Meeting Abstract

    D'Angelo, S. P.; Van Tine, B. A.; Attia, S.; Blay, J. Y.; Strauss, S. J.; Morales, C. M. V.; Razak, A. R. A.; Van Winkle, E.; Trivedi, T.; Biswas, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis
    Meeting Abstract

    D'Angelo, S. P.; Druta, M.; Van Tine, B. A.; Liebner, D. A.; Schuetze, S.; Hasan, A. N.; Holmes, A. P.; Huff, A.; Kapoor, G. S.; Zajic, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • ENVASARC: A pivotal trial of envafolimab, and envafolimab in combination with ipilimumab, in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy
    Meeting Abstract

    D'Angelo, S. P.; Robinson, S. I.; Lam, J.; Adams, B. J.; Freddo, J. L.; Theuer, C. P.; Maki, R. G.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Imaging-based patient inclusion model for clinical trial performance optimization
    Meeting Abstract

    Tomaszewski, M. R.; Fan, S.; Qi, J.; Garcia, A.; Kim, Y.; Schabath, M. B.; Gatenby, R. A.; Tap, W. D.; Reinke, D. K.; Makanji, R. J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations
    Meeting Abstract

    Dickson, M. A.; Ravi, V.; Ganjoo, K. N.; Iyer, G.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma
    Meeting Abstract

    Rosenbaum, E.; Movva, S.; Kelly, C. M.; Dickson, M. A.; Keohan, M. L.; Gounder, M. M.; Thornton, K. A.; Chi, P.; Chan, J. E.; Nacev, B.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after > 5 years of follow-up
    Journal Article

    D'Angelo, S. P.; Bhatia, S.; Brohl, A. S.; Hamid, O.; Mehnert, J. M.; Terheyden, P.; Shih, K. C.; Brownell, I.; Lebbé, C.; Lewis, K. D.; more...
    ESMO Open (2021)

    Fulltext@MSK | Save
  • Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: An analysis of the INVICTUS Study
    Journal Article

    Zalcberg, J. R.; Heinrich, M. C.; George, S.; Bauer, S.; Schöffski, P.; Serrano, C.; Gelderblom, H.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    The Oncologist (2021)

    Fulltext@MSK | Save
  • Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
    Journal Article

    Yin, O.; Zahir, H.; French, J.; Polhamus, D.; Wang, X.; van de Sande, M.; Tap, W. D.; Gelderblom, H.; Wagner, A. J.; Healey, J. H.; more...
    CPT: Pharmacometrics and Systems Pharmacology (2021)

    Fulltext@MSK | Save